Blog
Breaking: Oncology Startup Flindr Raises €20m for Cancer Treatment Breakthrough
📢 Flindr Therapeutics BV secures €20m Series A financing! 💰 Funding to advance first-in-class RNF31 inhibitors for cancer treatment. 🩸🔬
Breakthrough: Bacteria Transform Greenhouse Gases into Valuable Chemicals
Scientists at ETH Zurich have engineered bacteria to produce valuable chemicals from renewable feedstock, reducing dependence on fossil fuels. 🌱🔬
Medicare to Increase Reimbursement for Cell & Gene Therapy in 2025
📰 CMS proposes increasing reimbursement for cell & gene therapies for Medicare, aligning Medicaid plans for sickle cell disease. 💰 🏥 Payments for gene therapy could increase to 75 of cost. 🩺 Aim is to provide practical reimbursement strategy. 💡
Revolutionary Cell Therapy Startup Boosts Efficiency with Smart Operations
🔍 A cell therapy startup energized via smarter operations, using parallel working and Design of Experiment methodologies. 👩🔬📊🧪💡🔬🚀
Revolutionizing Protein Production: Genetic Engineering Unlocks Commercial-Scale Plant-Based Power
🌱 Genetic engineering can revolutionize plant-based protein production, offering scalability, cost benefits, and complex protein production. 🌱
Discover the Surprising Dual Nature of One Bacterium
🔍 Researchers discover a bacterium with dual nature: harmful in hospitals, but with potential in dyeing fabrics and medicine. 🧫💉🌈
Nordic Bioproducts Group revolutionizes cellulose production cutting emissions by 72
1. 🌱 Nordic Bioproducts Group 🚀 opens its first production facility in Lappeenranta! ♻️ Expecting €40m revenue and 🌍📉 emissions reduction. 2. Nordic Bioproducts Group opens its first production facility in Lappeenranta, generating revenue and reducing emissions with innovative technology.
Spanish Company Revolutionizes Personalized Medicine
📢 A Spanish company, TECNIC Bioprocess Solutions, has been selected for phase 1 of a pre-commercial public procurement for the development of an intelligent platform for single-use bioreactors. 👨⚕️ The collaboration between TECNIC Bioprocess Solutions and BYOTIC aims to advance personalized medicine and innovative therapies. 🔬 The project focuses on the development of single-use bioreactors for autologous cell therapy, reducing the need for repeated sterilization and contamination risks. 💡 TECNIC's innovative design incorporates advanced perfusion technology and control software for optimal production of cell-based biopharmaceuticals. ♻️ The modular and flexible design of the bioreactors enhances sustainability and adaptability, reducing costs and improving production efficiency. 🤝 Strategic collaborations with leading institutions such as Universitat Autònoma de Barcelona and Banc de Sang i Teixits de Catalunya strengthen research and development capabilities. 💪 This project not only improves personalized treatments but also sets new standards for efficient and safe production of biopharmaceuticals. 🌍 TECNIC's advancements in bioprocessing technology contribute to a future where personalized medicine is accessible to all, transforming healthcare. 💼 TECNIC Bioprocess Solutions' contribution to knowledge creation and technology transfer fosters economic and technological development.
Swiss Biotech Breaks Records with Massive Growth!
📢 Swiss biotech industry breaks records with CHF7.3bn turnover in 2023! 💰 Capital investment soars to CHF2bn, fueled by collaboration and product approvals. 🌍 High exports and global participation at Swiss Biotech Day. Hope for the future! 🚀
Ipsen’s $18bn Pipeline Expansion Targets Movement Disorders
🔬 Ipsen SA and Skyhawk Therapeutics Inc join forces in a groundbreaking $1.8bn deal to treat rare neurological disorders. 💪🧠
